Zenas BioPharma, Inc.
ZBIO
$19.16
-$1.24-6.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -426.56% | -20.05% | |||
| Gross Profit | 426.56% | 20.05% | |||
| SG&A Expenses | 18.32% | 8.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 49.88% | -13.75% | |||
| Operating Income | -49.88% | 13.75% | |||
| Income Before Tax | -366.68% | 1.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -366.89% | 1.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -366.89% | 1.39% | |||
| EBIT | -49.88% | 13.75% | |||
| EBITDA | -49.89% | 13.75% | |||
| EPS Basic | -271.40% | 2.08% | |||
| Normalized Basic EPS | -26.03% | 11.55% | |||
| EPS Diluted | -271.40% | 2.08% | |||
| Normalized Diluted EPS | -26.03% | 11.55% | |||
| Average Basic Shares Outstanding | 25.71% | 0.70% | |||
| Average Diluted Shares Outstanding | 25.71% | 0.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||